Amino Acid Injection Shortage: Status Updates for Premasol, Aminosyn-PF, and Other Brands
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
The FDA reports ongoing supply issues for certain Amino Acid Injection products, with some formulations currently unavailable or in limited supply while others remain available.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Amino Acid Injection) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
Amino Acid Injection, a medication within the gastroenterology therapeutic category, is currently experiencing supply disruptions. This shortage affects several brand-name products, including PREMASOL, PLENAMINE, AMINOSYN II, CLINISOL, TROPHAMINE, AMINOSYN-PF, TRAVASOL, and PROSOL. The shortage was first posted on December 8, 2020, and was most recently updated on February 2, 2026.
Which Manufacturers Are Affected
Availability varies significantly by manufacturer and specific product presentation:
Baxter Healthcare: Most presentations of Premasol, Clinisol, Prosol, and Travasol are currently Available. However, one presentation of Travasol (NDC 0338-0644-06) is under Limited Availability with an estimated recovery date of February 2026.
- Contact: 888-229-0001
Otsuka ICU Medical LLC (Distributed by ICU Medical): Aminosyn II (10% and 15%) is currently Available. However, Aminosyn-PF 7% (NDC 0990-4178-03) and Aminosyn-PF 10% (NDC 0990-4179-05) are currently Unavailable with the recovery date to be determined (TBD).
- Contact: 1-866-829-9025 or ProductAvailability@icumed.com
B. Braun Medical Inc.: All listed presentations of Plenamine and TrophAmine 10% are currently Available.
- Contact: 800-227-2862
Why There's a Shortage
The FDA source data does not provide a specific reason for the current shortage of these amino acid injection products.
What Patients Should Do
Patients who rely on these injections for nutritional support should be aware that while many versions are available, specific formulations (particularly Aminosyn-PF) may be difficult to obtain.
- Consult Your Healthcare Provider: Speak with your doctor or specialist regarding the availability of your specific formulation. They can determine if an available brand or concentration is appropriate for your clinical needs.
- Talk to Your Pharmacist: Pharmacists often have the most up-to-date information on which NDCs (National Drug Codes) are currently in stock or can be ordered.
- Contact Manufacturers: If you are having difficulty locating a specific product, you may use the contact information provided above to inquire about regional availability.
Disclaimer: This information is for educational purposes only. Patients should always consult with their healthcare provider or pharmacist for medical advice and guidance regarding medication changes or alternatives.
Source
Information provided by the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category